Acinetobacter Infections - Pipeline Review, H1 2017

Publisher Name :
Date: 16-May-2017
No. of pages: 119
Price : Single User: US $ 2000  US $ 1600 Corporate User: US $ 6000  US $ 4500
Inquire Before Buying
This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 28 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 8 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Acinetobacter Infections - Pipeline Review, H1 2017

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acinetobacter Infections - Overview 7
Acinetobacter Infections - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Acinetobacter Infections - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Acinetobacter Infections - Companies Involved in Therapeutics Development 25
Achaogen Inc 25
Adenium Biotech ApS 25
Aridis Pharmaceuticals LLC 26
Atterx Biotherapeutics Inc 26
AvidBiotics Corp 27
Emergent BioSolutions Inc 27
Entasis Therapeutics Inc 28
Evaxion Biotech ApS 28
F. Hoffmann-La Roche Ltd 29
FOB Synthesis Inc 29
Hsiri Therapeutics LLC 30
LegoChem Biosciences Inc 30
Melinta Therapeutics Inc 31
Nosopharm SAS 31
Novabiotics Ltd 32
Omnia Molecular Ltd 32
Peptilogics Inc 33
Pfizer Inc 33
Redx Pharma Plc 34
Sarepta Therapeutics Inc 34
Sealife PHARMA GMBH 35
Shionogi & Co Ltd 35
Techulon Inc 36
Tetraphase Pharmaceuticals Inc 36
Vaxdyn SL 37
Xellia Pharmaceuticals ApS 37
Acinetobacter Infections - Drug Profiles 38
A-3APO - Drug Profile 38
AA-139 - Drug Profile 40
AB-877 - Drug Profile 41
Acinetobacter vaccine - Drug Profile 42
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 43
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 44
AR-401 - Drug Profile 45
AvR2-V10 - Drug Profile 46
CA-824 - Drug Profile 48
cefiderocol - Drug Profile 49
CSA-13 - Drug Profile 52
EBX-004 - Drug Profile 54
ETX-2514 + sulbactam sodium - Drug Profile 55
EV-035 - Drug Profile 57
FAB-001 - Drug Profile 59
FSI-1671 - Drug Profile 60
FSI-1686 - Drug Profile 61
G-3KL - Drug Profile 62
GN-4474 - Drug Profile 63
HT-06 - Drug Profile 64
HT-07 - Drug Profile 65
HT-10 - Drug Profile 66
JSM-11 - Drug Profile 67
LCB-100200 - Drug Profile 68
MDN-0057 - Drug Profile 69
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 71
NOSO-95179 - Drug Profile 72
NP-432 - Drug Profile 73
Peptides for Infectious Diseases - Drug Profile 74
pneumonia vaccine - Drug Profile 75
RX-05 - Drug Profile 76
RXP-873 - Drug Profile 77
SLP-0901 - Drug Profile 78
SLP-0905 - Drug Profile 79
Small Molecule for Acinetobacter baumannii Infections - Drug Profile 80
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 81
Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile 82
Small Molecules for Acinetobacter baumannii Infection - Drug Profile 83
Small Molecules for Bacterial and Fungal Infections - Drug Profile 84
Small Molecules for Bacterial Infections - Drug Profile 85
Small Molecules for Bacterial Infections - Drug Profile 86
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 87
Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 88
Small Molecules to Inhibit DNA Gyrase Subunit A and Topoisomerase IV for Gram-Negative Bacterial Infections - Drug Profile 89
Small Molecules to Inhibit LpxC for Gram Negative Bacterial Infections - Drug Profile 90
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections and Respiratory Diseases - Drug Profile 91
Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 92
SPR-741 - Drug Profile 93
Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 96
Synthetic Peptides for Infectious Disease - Drug Profile 97
TN-5 - Drug Profile 98
TP-6076 - Drug Profile 99
VNRX-5113 - Drug Profile 100
VXD-001 - Drug Profile 101
VXD-003 - Drug Profile 102
XEL-1001 - Drug Profile 103
XEL-1002 - Drug Profile 104
XEL-1003 - Drug Profile 105
XEL-1007 - Drug Profile 106
Acinetobacter Infections - Dormant Projects 107
Acinetobacter Infections - Product Development Milestones 109
Featured News & Press Releases 109
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115

List of Tables

Number of Products under Development for Acinetobacter Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Acinetobacter Infections - Pipeline by Achaogen Inc, H1 2017
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2017
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2017
Acinetobacter Infections - Pipeline by AvidBiotics Corp, H1 2017
Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H1 2017
Acinetobacter Infections - Pipeline by Evaxion Biotech ApS, H1 2017
Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Acinetobacter Infections - Pipeline by FOB Synthesis Inc, H1 2017
Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
Acinetobacter Infections - Pipeline by LegoChem Biosciences Inc, H1 2017
Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2017
Acinetobacter Infections - Pipeline by Novabiotics Ltd, H1 2017
Acinetobacter Infections - Pipeline by Omnia Molecular Ltd, H1 2017
Acinetobacter Infections - Pipeline by Peptilogics Inc, H1 2017
Acinetobacter Infections - Pipeline by Pfizer Inc, H1 2017
Acinetobacter Infections - Pipeline by Redx Pharma Plc, H1 2017
Acinetobacter Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, H1 2017
Acinetobacter Infections - Pipeline by Techulon Inc, H1 2017
Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Acinetobacter Infections - Pipeline by Vaxdyn SL, H1 2017
Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H1 2017
Acinetobacter Infections - Dormant Projects, H1 2017
Acinetobacter Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017

List of Figures

Number of Products under Development for Acinetobacter Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open ......
  • Escherichia coli Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 152
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated......
  • Tularaemia - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H1 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal ......
  • Diphtheria - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H1 2017, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever ......
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 79
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2017, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of V......
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 374
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as commun......
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 40
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2017, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline landscape.Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other seriou......
  • Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 97
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.......
  • Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 164
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2017, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The pr......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs